Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion

Ioanna Mavrommati1,†, Ouma Cisse1, Marco Falasca1,2 & Tania Maffucci1

Phosphoinositide 3-kinases (PI3Ks) regulate several cellular functions such as proliferation, growth, survival and migration. The eight PI3K isoforms are grouped into three classes and the three enzymes belonging to the class II subfamily (PI3K-C2α, β and γ) are the least investigated amongst all PI3Ks. Interest on these isoforms has been recently fuelled by the identification of specific physiological roles for class II PI3Ks and by accumulating evidence indicating their involvement in human diseases. While it is now established that these isoforms can regulate distinct cellular functions compared to other PI3Ks, there is still a limited understanding of the signalling pathways that can be specifically regulated by class II PI3Ks. Here we show that PI3K-C2β regulates mitogen-activated protein kinase kinase (MEK1/2) and extracellular signal-regulated kinase (ERK1/2) activation in prostate cancer (PCa) cells. We further demonstrate that MEK/ERK and PI3K-C2β are required for PCa cell invasion but not proliferation. In addition we show that PI3K-C2β but not MEK/ERK regulates PCa cell migration as well as expression of the transcription factor Slug. These data identify novel signalling pathways specifically regulated by PI3K-C2β and they further identify this enzyme as a key regulator of PCa cell migration and invasion.

Phosphoinositide 3-kinases (PI3Ks), the lipid kinases that catalyse the synthesis of the phosphoinositides phosphatidylinositol 3-phosphate, phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3), have a well-established role in regulation of several cellular processes, including cell proliferation, growth, survival, migration and metabolism1–3. Deregulation of PI3Ks-dependent signals is associated with several diseases including cancer4–8 and indeed inhibitors of this pathway have been developed as anti-cancer drugs and are currently in clinical trials9–11. Unfortunately the use of these inhibitors has also led to the discovery of compensatory mechanisms that reduce their therapeutic efficiency12,13. As a consequence an increasing interest has emerged to better define the potential contribution of each of the eight mammalian PI3K isoforms to cancer development and progression and ultimately to identify more selective and targeted therapeutic strategies2,14,15. Generation of isoform specific knock-out and knock-in mice and the development of isoform-specific inhibitors have greatly improved our knowledge of the physiological roles and the cellular functions that are specifically regulated by each PI3K16,17. On the other hand much less is known about specific signalling pathways that can be activated selectively by each PI3K isoform.

The three isoforms grouped into the class II subfamily (PI3K-C2α, β and γ) have been the least investigated amongst all PI3Ks for many years2,15. Lately interest on these enzymes has progressively increased and indeed recent studies have shed light into their specific physiological roles11. Attempt to generate homozygous PI3K-C2α knock-out19–21 or kinase-inactivating knock-in22 mice resulted in embryo lethality revealing a specific requirement for this enzyme in embryo development. On the other hand both PI3K-C2β−/−23 and PI3K-C2γ−/−24 mice were viable supporting the conclusion that the class II isoforms have distinct cellular functions. Further investigation identified a pivotal role for PI3K-C2α in endothelial cells, angiogenesis and vascular barrier function19, in regulation of primary cilium function20 and, more recently, in regulation of platelets membrane structure.
morphology and adhesion. Investigation of PI3K-C2−/− mice established that the enzyme is not required for growth, differentiation, barrier function and wound healing in the epidermis. PI3K-C2− appears to have a specific role in glucose homeostasis regulation since PI3K-C2−/− mice develop hyperlipidemia, adiposity and insulin resistance with age or following high fat diet. These studies have all reinforced the conclusion that each class II PI3K isoforms can regulate distinct cellular functions compared to other PI3Ks and have fuelled interest towards a better characterisation of these enzymes. A better understanding of potential contribution of class II PI3Ks to human diseases is also urged by accumulating evidence indicating a role for some of these enzymes in cancer. It has been reported that subsets of cell and cell lines from small cell lung cancer (SCLC), acute myeloid leukemia, glioblastoma multiforme, medulloblastoma as well as primary neuroblastoma tumours and cell lines are characterised by increased levels of PI3K-C2. Consistently, gene expression profiling indicated increased expression of PI3K-C2 in acute lymphocytic leukemia, acute myeloid leukemia and glioblastoma and recurrent mutations (12.9%) in PIK3CB have been observed in lung cancer. Furthermore PI3K-C2 has been implicated in cancer cell migration and in neuroblastoma tumourigenesis. Importantly inhibition of PI3K-C2 has been shown to inhibit early stage of neuroblastoma formation and ovarian cancer metastasis formation in animal models, supporting the conclusion that this enzyme may represent a novel interesting target in anti-cancer therapy. Despite this evidence there is still a very limited understanding of the signalling pathways that can be specifically regulated by PI3K-C2.

Here we show that PI3K-C2 regulates mitogen-activated protein kinase kinase (MEK1/2) and extracellular signal-regulated kinase (ERK1/2) activation induced by foetal bovine serum (FBS) or epidermal growth factor (EGF) in prostate cancer (PCa) cells lines. Inhibition of MEK/ERK activation as well as downregulation of PI3K-C2 does not affect cell proliferation while specifically inhibiting cell invasion. We further show that PI3K-C2 regulates FBS-induced PCa cell migration (Supplementary Fig. S1a) as well as four control clones (sh scrambled, Fig. 1b, Supplementary Fig. S1a).

Results
PI3K-C2 regulates MEK/ERK activation in PCa cells. The signalling pathways specifically regulated by PI3K-C2 are still not completely defined. While previous studies have mainly focussed their attention on its potential contribution to activation of the well established class I PI3K target Akt and Rho GTPases and PI3K-C2 activity of potential role of PI3K-C2 on activation of a panel of 43 distinct kinases and 2 related proteins using a phosphokinese antibody array. The choice of the cellular model was prompted by a recent study suggesting a potential association between PI3K-C2 and PCa risk. First we analysed the expression levels of PI3K-C2 in three distinct PCa cell lines compared to PNT2, an immortalised prostate cell line. PI3K-C2 was highly expressed in PC3 and LNCaP cell lines, both lacking the tumour suppressor phosphatase and tensin homolog (PTEN), the phosphatase responsible for dephosphorylation of PtdIns(3,4,5)P3 compared to the PTEN expressing PCa cell line DU145 and to PNT2 cells (Fig. 1a). Interestingly we also noticed that PI3K-C2 was barely detectable in DU145 and PNT2 when cells were lysed with 1% Triton X-100 whereas it was clearly observed when cells were lysed with 2% SDS (Fig. 1a), suggesting a specific localisation of the enzyme within Triton-insoluble cellular fractions in these cells.

Based on PI3K-C2 expression we selected PC3 cells for phosphokinase antibody array analysis. We reasoned that the constitutive hyperactivation of the class I PI3Ks-dependent pathways due to the lack of PTEN could facilitate the identification of pathways specifically modulated by PI3K-C2 upon growth factor stimulation. To determine the role of PI3K-C2 we generated stable PC3 cell lines by transfecting parental cells with a shP3 vector carrying a shRNA specifically targeting the enzyme. Control cells were transfected with a vector containing a non-targeting shRNA. Cell populations expressing the PI3K-C2-targeting shRNA or control shRNA were selected by incubation in media supplemented with puromycin and then allowed to grow as single clones. Four distinct knockdown clones were then selected, all displaying a high efficiency of PI3K-C2 downregulation (sh PI3K-C2, Fig. 1b, Supplementary Fig. S1a) as well as four control clones (sh scrambled, Fig. 1b, Supplementary Fig. S1a).

No effect on the expression levels of the class I isoforms p110α, p110β and the class II enzyme PI3K-C2α was detected in the knockdown clones (Supplementary Fig. S1b,c) and no difference in the expression of PI3K-C2 between control clones and parental cells was observed (Fig. 1b).

Once stable cell lines were established one sh PI3K-C2 clone and one sh scrambled clone were serum starved overnight and either left untreated or stimulated with DMEM containing 10% FBS for 10 min. Activation of a panel of kinases was then analysed in the corresponding lysates (Supplementary Fig. S1d). Densitometry analysis of the phosphoarray indicated only slight differences in the FBS-induced activation of the classical class I PI3K signalling pathways (Supplementary Fig. S1e). On the other hand a clear inhibition of FBS-induced phosphorylation of some members of the mitogen-activated protein kinases (MAPK) family was observed in cells lacking PI3K-C2 (Supplementary Fig. S1f). In particular FBS-induced p38α and MEK1/2 phosphorylation appeared to be strongly reduced in cells lacking PI3K-C2 (Supplementary Fig. S1f).

Stable PI3K-C2 downregulation inhibits MEK and ERK activation. To validate the results of the array we then performed a time course experiment using two distinct knockdown clones and two control clones (Supplementary Fig. S1g,h). Data revealed a very rapid and transient phosphorylation of ERK1/2 at residues Thr202/Tyr204 and a more sustained phosphorylation of MEK1/2 at residues Ser217/221 (Supplementary Fig. S1g,h). Importantly FBS-induced phosphorylation of both MEK1/2 and ERK1/2 was reduced in cells lacking PI3K-C2 (Supplementary Fig. S1g,h). Validation of these results in distinct PI3K-C2 knockdown clones indicated a significant reduction of MEK1/2 phosphorylation upon 5 and 10 min of FBS stimulation (Fig. 1c,d), as confirmed by densitometry analysis (Fig. 1e,f). Similarly a clear inhibition of FBS-induced ERK1/2...
Figure 1. PI3K-C2β is required for FBS-induced MAPK activation. (a) Representative blot of PI3K-C2β and PTEN levels in the indicated prostate cell lines upon lysis with 1% Triton X-100 or 2% SDS. Tubulin or Actin were used as loading control. (b) Stable PC3 clones expressing a specific shRNA targeting PI3K-C2β or a control shRNA (sh scrambled) were generated as described in the Methods. Representative blots showing expression levels of PI3K-C2β in the indicated stable PC3 cells. Numbers indicate the specific clone. (c–j) The indicated PC3 stable clones were serum starved overnight and then stimulated with FBS for the indicated times. Phosphorylation of MEK1/2 at residues Ser217/221 (c–f) and ERK1/2 at residues Thr202/Tyr204 (g–j) was assessed by Western blotting. Tubulin was used as loading control. In some experiments membranes incubated with pERK1/2 were stripped and then incubated with antibody recognising total ERK2. Representative blots are shown. Results from densitometry analysis are expressed as fold change of the specific sh scrambled clone used in each experiment and are means ± s.e.m. from the following number of experiments: (e): n = 3 (PC3 and clone 4), n = 4 (clones 1,3), n = 2 (clone 2); (f): n = 3 (PC3, clones 1,4), n = 4 (clone 2), n = 6 (clone 3); (i): n = 2 (PC3, clones 1,2,4), n = 3 (clone 3); (j): n = 3 (PC3, clone 1), n = 12 (clone 2), n = 11 (clone 3), n = 2 (clone 4). *p < 0.05, **p < 0.01, ***p < 0.001.
phosphorylation was detected in cells lacking PI3K-C2β (Fig. 1g–j). No major differences were observed in MEK1/2 and ERK/12 phosphorylation between parental and control sh scrambled cells (Fig. 1c–j).

To further validate the role of PI3K-C2β in ERK1/2 activation stable PC3 clones were stimulated with epidermal growth factor (EGF). Consistent with data obtained upon FBS stimulation, EGF-induced MEK1/2 (Fig. 2a,b) and ERK1/2 (Fig. 2c,d) phosphorylation was strongly reduced in cells lacking PI3K-C2β. Importantly the reduced phosphorylation was not due to reduced total ERK levels in sh PI3K-C2β stable cell lines (Fig. 2e–h, Supplementary Fig. S2a).

Taken together these data indicate that PI3K-C2β regulates MEK/ERK activation upon FBS and EGF stimulation.
Transient PI3K-C2β downregulation inhibits MEK1/2 and ERK1/2 activation. In order to rule out any potential non-specific effect due to the stable downregulation of PI3K-C2β, we next investigated the effect of transient downregulation of the enzyme on MEK1/2 and ERK1/2 phosphorylation. Consistent with data obtained using the stable clones, PI3K-C2β downregulation using two distinct siRNAs significantly inhibited FBS-induced MEK1/2 (Fig. 2i,j) and ERK1/2 phosphorylation (Fig. 2k,l) compared to cells transfected with a non-targeting, negative control siRNA (si NC). As for stable cells, transient downregulation of PI3K-C2β did not reduce total ERK levels (Fig. 2m).

To further investigate the role of PI3K-C2β in MAPK activation in PCA cells, we determined the effect of its transient downregulation in LNCaP cells that express high levels of PI3K-C2β and do not express PTEN (Fig. 1a). Preliminary experiments revealed a strong phosphorylation of ERK1/2 upon EGF stimulation in these cells (Supplementary Fig. S2b). Consistent with data in PC3, the EGF-induced ERK1/2 phosphorylation was significantly reduced in LNCaP upon transient downregulation of PI3K-C2β with two distinct siRNAs (Fig. 2n,o).

We next investigated whether other PI3K isoforms were also involved in regulation of ERK phosphorylation. To this end PC3 cells were treated with the PI3K inhibitor LY294002 before stimulation with FBS or EGF. The concentration of LY294002 used (5 μM) is reported not to affect PI3K-C2β activation41,42 while being able to inhibit class I and class III PI3K isoforms. Indeed treatment of cells with LY294002 (5 μM) clearly inhibited phosphorylation of Akt at its residue Ser473 (Supplementary Fig. S2c–e). In contrast the inhibitor did not affect either the FBS- or the EGF-induced ERK1/2 phosphorylation (Supplementary Fig. S2f–h) suggesting that class I and class III PI3Ks are not involved in ERK1/2 activation in PC3 cells.

Taken together these data indicate a specific role for PI3K-C2β in regulation of MEK/ERK activation in PCA cells.

The PI3K-C2β/ERK pathway does not regulate cell growth in PCA cells. We next investigated whether the PI3K-C2β-depended MEK/ERK activation had a role on PCA cell growth. Interestingly, incubation of PC3 cells for 72 h in growth media supplemented with the MEK1/2 inhibitor U0126 did not reduce the number of cells (Fig. 3a). Similarly transient downregulation of PI3K-C2β did not reduce the number of cells as determined 72 h following transfection (Fig. 3b). Efficiency of PI3K-C2β downregulation was assessed by Western blotting analysis (Fig. 3c). Consistent with this, cell counting (Fig. 3d) and MTT assays (Fig. 3e) revealed no difference in proliferation in growth media between parental PC3, two distinct sh PI3K-C2β stable clones. Levels of PI3K-C2β in the indicated clones was assessed by Western blotting analysis (Fig. 3f). Furthermore no statistically significant difference in the percentage of cells in the G1, S and G2/M phases of the cell cycle (Fig. 3g) or in the percentage of apoptotic cells (Fig. 3h) was detected in PC3 cells upon transient downregulation of PI3K-C2β. As a control downregulation of the class I PI3K isoform p110β performed in parallel was clearly able to induce apoptosis in these cells (Fig. 3h). Western blotting analysis confirmed efficient downregulation of PI3K-C2β and p110β (Fig. 3i).

Taken together these data indicate that the PI3K-C2β/MEK/ERK pathway does not regulate PC3 cell proliferation, at least in normal growing conditions.

MEK/ERK and PI3K-C2β are involved in PCA invasion. Although the MEK/ERK pathway is usually associated with cell proliferation data in literature also indicate a role for these kinases in regulation of cell motility and migration. We therefore decided to determine whether this pathway was required for PC3 cell invasion. Inhibition of MEK1/2 with the specific inhibitor U0126 significantly reduced FBS-induced cell invasion (Fig. 4a) without affecting cell proliferation assessed in parallel (Fig. 4b). Efficiency of the inhibitor was confirmed by Western blotting analysis of lysates from cells plated in parallel and stimulated with FBS (Fig. 4c). These data indicate a role for MEK/ERK in PCA cell invasion.

We next investigated whether PI3K-C2β was also involved in this process. As shown in Fig. 4d,e, transient downregulation of PI3K-C2β with two distinct siRNAs strongly reduced FBS-induced cell invasion in PC3 cells. No statistically significant difference was observed in invasion of cells transfected with control siRNA (si NC) compared to cells (control) treated with the transfection reagent alone (Fig. 4d,e). A strong inhibition of FBS-induced invasion was also detected in three distinct sh PI3K-C2β stable clones compared to control sh scrambled cells (Fig. 4f,g). Representative images are shown in Fig. 4f. Quantification of these assays indicated a very strong inhibition of invasion in cells lacking PI3K-C2β (Fig. 4g). No difference was detected between stable control cells compared to parental PC3 cells (Fig. 4g). On the other hand downregulation of PI3K-C2β did not affect basal invasion induced by Matrigel alone (Fig. 4h), indicating a specific role for PI3K-C2β in growth factors-induced cell invasion. Consistent with this, we observed that EGF-induced invasion was also reduced in cells lacking PI3K-C2β (Fig. 4i). In addition downregulation of PI3K-C2β using two distinct siRNAs reduced the FBS-induced invasion in LNCaP cells (Fig. 4i). Efficient downregulation of PI3K-C2β in this cell line was confirmed by Western blotting (Fig. 4k).

Taken together these data indicate that MEK/ERK and PI3K-C2β are required for PCA cell invasion.

PI3K-C2β regulates PCA cell migration. Several studies have reported that PI3K-C2β regulates cell migration in different cell types31–33,37,40. Therefore we next investigated whether the effect of PI3K-C2β downregulation on PCA cell invasion was due to a specific role of the enzyme in regulation of cell migration in these cells. Transwell assays revealed a clear reduction in FBS-induced migration of PC3 cells upon downregulation of PI3K-C2β using two distinct siRNAs (Fig. 5a,b). Similarly, reduced migration was observed in two distinct sh PI3K-C2β clones compared to sh scrambled cell lines (Fig. 5c). Representative images of migrated cells are also shown in Fig. 5c. Consistent with data from Transwell assays, cells lacking PI3K-C2β also displayed impaired FBS-induced migration in wound healing assays (Fig. 5d,e). On the other hand no major differences were detected in the distance and velocity of parental and stable cell lines in single cell-motility assays (Fig. 5f),
Figure 3. MEK/ERK and PI3K-C2β are not required for PCa cell proliferation. (a) PC3 cells were incubated in growth media supplemented with MEK1/2 inhibitor U0126 (25 μM) or vehicle control (DMSO) for 72 h before counting. Data are expressed as fold change of number of cells treated with DMSO and are means ± s.e.m. from n = 3 independent experiments. (b,c) PC3 cells were transiently transfected with a specific siRNA targeting PI3K-C2β (sequence 1), a non-targeting, negative control siRNA (si NC) or transfection reagent (control) alone. The number of cells was determined by manual counting after 72 h in growth media. Data are expressed as fold change of number of control cells and are means ± s.e.m. of n = 4 independent experiments. Efficient downregulation of PI3K-C2β was confirmed by Western blotting analysis. Tubulin was used as loading control. (d) Data from cell counting are expressed as fold change of number of cells plated at day 0 and are means ± s.e.m. of n = 7 (PC3), n = 11 (sh scrambled clone 2), n = 8 (sh PI3K-C2β clone 2) and n = 5–6 (sh PI3K-C2β clone 3) independent experiments. (e) Data from MTT assay are expressed as fold change of absorbance determined at day 1 and are means ± s.e.m. of n = 3–4 experiments. (f) Representative blot showing expression levels of PI3K-C2β in the indicated cell lines. (g) PC3 cells were transiently transfected as before and fixed after 72 h. Cell cycle analysis was performed by FACS as described in the Methods section. Data are expressed as percentage of cells in the distinct phases and are means ± s.e.m. of n = 4 independent experiments. (h) PC3 cells were transiently transfected with the indicated siRNAs. The percentage of apoptotic cells was determined 48 h after transfection by Annexin V/FACS analysis as described in the Methods section. Data are expressed as percentage of early + late apoptotic cells and are means ± s.e.m. of n = 3–4 independent experiments. Data from one experiment with siRNA PI3K-C2β (sequence 1) and two experiments with siRNA PI3K-C2β (sequence 2) are pulled together. (i) Efficiency of PI3K-C2β and p110β downregulation was assessed by Western blotting.
consistent with previous observations in endothelial cells. Similarly downregulation of \( \text{PI3K-C2} \) did not affect migration induced by Type I collagen (Fig. 5g), indicating a specific role for this enzyme in FBS-dependent PCa cell migration.

We then determined whether MEK/ERK were also involved in this process. Interestingly treatment of cells with the MEK1/2 inhibitor U0126 did not affect the FBS-induced migration of PC3 cells assessed by Transwell assays (Fig. 5h). Consistent with data presented above (Figs 3a and 4b) incubation with the inhibitor did not affect cell numbers (Fig. 5i). Efficiency of the inhibitor was confirmed in experiments performed in parallel (Fig. 5j).

These data demonstrate that MEK/ERK are involved in invasion but not migration of PCa cells and suggest that \( \text{PI3K-C2} \) can control cell invasion partly by regulating the MEK/ERK pathway and partly by activating additional signalling pathways that modulate PCa cell migration.
PI3K-C2β specifically regulates the expression levels of the transcription factor Slug. In an effort to further characterise the signalling pathways regulated by PI3K-C2β and involved in cell migration/invasion we next determined whether downregulation of this enzyme might affect the expression levels of proteins involved in epithelial-mesenchymal transition (EMT), a process by which epithelial cells can acquire migratory and invasive properties. No major differences in the expression levels of the transcription factors TCF8/ZEB1 (Supplementary Fig. S3a,b) and ZO-1 (Supplementary Fig. S3d,e), β catenin (Supplementary Fig. S3a,c), Vimentin (Supplementary Fig. S3d,f) and Claudin-1 (Supplementary Fig. S3g,h) was detected in sh PI3K-C2β compared to sh scrambled cells by Western blotting analysis. Similarly downregulation of PI3K-C2β did not affect mRNA levels of β catenin (Supplementary Fig. S3i), Vimentin (Supplementary Fig. S3j) and Twist (Supplementary Fig. S3k).
indicated a role for this enzyme in migration of several cell types. This is the first study demonstrating a kinase inactive mutant of PI3KC2β in H-69 SCLC cells did not inhibit the stem cell factor-induced ERK1/2 phosphorylation or activation assessed by in vitro kinase assay. Consistent with these data, no effect on sphingosine 1-phosphate-dependent ERK1/2 phosphorylation was detected in human umbilical vein endothelial cells upon downregulation of PI3KC2β. Transient transfection of specific siRNA or in EGF-mediated ERK1/2 phosphorylation in SK-N-AS and IMR-5 neuroblastoma cell lines stably infected with shRNAs targeting PI3KC2β. On the other hand both basal and EGF-mediated ERK1/2 activation appeared to be inhibited in A-431 cells overexpressing either wild type or kinase dead PI3KC2β D1213A-17 and D1213A-32. Furthermore EGF- or platelet derived growth factor-induced ERK1/2 phosphorylation was increased in NIH3T3 overexpressing PI3KC2β and reduced in NIH3T3 overexpressing PI3KC2βDN. Our data here indicate a specific role for PI3KC2β in regulation of MEK/ERK in PCa cell lines PC3 and LNCaP. It is worth mentioning that PC3 and LNCaP are both PTEN null cells and appear to express increased levels of PI3KC2β compared to the PTEN-expressing PCa cell line DU145 or the prostate cell line PNT2. Whether PI3KC2β specifically regulates MEK/ERK in the context of PTEN deletion/mutation remains to be established.

We further show that downregulation of PI3KC2β inhibited PCa cell invasion. While data have previously indicated a role for this enzyme in migration of several cells types, this is the first study demonstrating that PI3KC2β is required for PCa cell invasion. Importantly we observed that inhibition of MEK/ERK also reduced PCa cell invasion, consistent with a previous study suggesting that downregulation of ERK2 in PC-3-ML, a subclone of PC3 able to metastasise to the lumbar vertebrae, resulted in reduced ability to form metastasis. Taken together these data indicate that the PI3KC2β-dependent MEK/ERK regulation is involved in regulation of PCa cell invasion. On the other hand neither PI3KC2β nor MEK/ERK appear to play a main role in PCa cell proliferation, at least in normal growing conditions. Interestingly we observed that downregulation of PI3KC2β resulted in a much stronger reduction of cell invasion compared to the effect of MEK/ERK inhibition. Indeed further investigation revealed that downregulation of PI3KC2β reduced both FBS-induced cell migration and invasion whereas MEK/ERK inhibition impaired cell invasion without affecting cell migration. This is consistent with a previous report demonstrating that ERK1/2 is not involved in EGF-induced migration of prostate cancer cell line DU145 and suggests that the PI3KC2β-regulation of MEK/ERK is involved in steps necessary for cell invasion other than cell migration. In this respect it is noteworthy that ERK1/2 has been previously reported to play a key role in ADAM17-dependent invasion of PCa cell through overexpression of metalloproteinases MMP-2 and MMP-9.
Figure 6. PI3K-C3 regulates levels of the transcription factor Slug. (a,b) Representative blots and results from densitometry analysis expressed as fold change of normalised levels of Slug in the shscrambled clone used in each set of experiments. Data are means ± s.e.m. from n = 5–10 independent experiments. *p < 0.01, **p < 0.001 vs shscrambled. (c,d) Representative blots and results from densitometry analysis expressed as fold change of normalised levels of Slug in cells transfected with si NC. Data are means ± s.e.m. from: n = 4–5 independent experiments. *p < 0.05. (e) Results from qPCR analysis expressed as fold change of normalised levels of Slug mRNA in PC3. Data are means ± s.e.m. from n = 3 independent experiments. shPI3K-C2β clone 1: *p < 0.05 vs PC3 and shscrambled clone 4; shPI3K-C2β clone 2: *p < 0.05 vs shscrambled clone 4, *p < 0.01 vs PC3 and shscrambled clone 2; shPI3K-C2β clone 3: *p < 0.05 vs shscrambled clone 4 and shscrambled clone.
Taken together these data suggest that PI3K-C2β can control cell invasion partly by regulating the MEK/ERK pathway and partly by activating additional signalling pathways that modulate PCa cell migration. It has been previously reported that PI3K-C2β can regulate cell motility by modulating activation of GTPases and actin remodelling32. Indeed PI3K-C2β has been recently identified as the main PI3K isoform involved in actin remodelling of ovarian cancer cells33 confirming its critical role in regulation of migration of these cells31,33. To further define the mechanisms involved in PI3K-C2β-dependent regulation of cell migration we investigated the potential contribution of this enzyme to EMT and we observed that downregulation of PI3K-C2β induced a specific reduction in the expression levels of the transcription factor Slug. Slug is a member of the Snail superfamily of zinc finger transcription factors that have a key role in EMT and in regulation of cell invasion and metastasis in several cancer types48–50. In particular we observed that downregulation of Slug inhibited invasion of PC3 cells, consistent with a previous study42 and with a report demonstrating that overexpression of Slug stimulates migration and invasion of PC3 cells43. Moreover it was proposed that inhibition of Slug might represent one of the main mechanisms by which combination of mTOR, ERK1/2 and Hsp90 inhibitors was able to reduce circulating tumour cells in xenograft mouse models implanted with PCa cell lines54. Here we show that downregulation of PI3K-C2β results in reduced expression levels of Slug in PC3 cells and this is the first evidence of a role for a class II PI3K in regulation of the expression of this transcription factor. These results together with our and previous data demonstrating the role of Slug in migration and invasion strongly suggest that modulation of Slug levels may be one of the mechanisms by which PI3K-C2β regulates these cellular processes. Furthermore, as we ruled out a main role for MEK/ERK in Slug regulation in PC3 cells, these data demonstrate that PI3K-C2β can control PCa cell migration and invasion through different cellular pathways.

Taken together our study has identified novel signalling pathways specifically activated by PI3K-C2β and it has revealed an important role for this enzyme in PCa cells. It has been estimated that roughly 40% of primary and 70% of metastatic PCa have genomic alterations of PI3K-dependent signalling pathway52. Complete loss or haploinsufficiency of PTEN occurs in 20–70% of primary PCa and 30–80% of locally advanced and metastatic disease53. Animal models have indicated the pivotal role of PTEN in PCa54–56. Homozygous Ptennull mice develop prostate intraepithelial neoplasia (PIN) that do not evolve to more aggressive forms of the disease mostly because of simultaneous development of other tumours. On the other hand, homozygous deletion of Pten in the mouse prostate led to PIN lesions at 6 weeks of age that progressed to invasive and metastatic prostate carcinoma within a few weeks55. The use of Pten hypomorphic alleles demonstrated that decreasing PTEN levels correlates with increased progression of prostate tumours in mice. Furthermore mouse models have also established that concurrent Pten hemizygosity coupled with deletions in other genes accelerates tumourigenesis. Further animal models revealed the critical role of the class I PI3K isoform p110α and not p110β in PTEN deletion-driven PCa development57. Indeed overexpression of p110α was able to induce early lesions of prostatic tumour formation in mice58. Several in vitro studies further confirmed the role of this enzyme and indicated a role in androgen-dependent gene expression, cell proliferation and survival59. Indeed a specific p110α inhibitor that has been modified to selectively target PCa cells has recently shown a very strong activity towards xenografts from different PCa cells60. As a consequence p110α is considered a very promising novel target in PCa59. Interestingly a recent study investigating the associations between single nucleotide polymorphisms in PI3K genes and PCa risk reported significant associations between a cluster of variants located upstream and in the promoter regions of PIK3CB, the gene encoding for PI3K-C2β, and PCa risk61. Despite this interesting evidence, very little was known on the role of PI3K-C2β in PCa. Our data here demonstrate that PI3K-C2β is also a key enzyme in PCa, playing distinct roles and activating distinct cellular pathways compared to class I isoforms. Specifically, our data indicate that, while p110α has a key role in PCa cell proliferation and survival, PI3K-C2β is specifically involved in regulation of cell migration and invasion. These data suggest that PI3K-C2β may represent a novel potential target in PCa possibly to counteract metastasis progression. It is noteworthy that inhibition of this enzyme has been recently proved able to reduce ovarian cancer-derived metastasis formation in mice33, providing the first evidence of the anti-metastatic potential of targeting this enzyme.

In conclusion our study not only has identified novel signalling pathways specifically regulated by the class II PI3K isoform PI3K-C2β but it has also revealed a key role for this enzyme in PCa, in particular PCa cell migration and invasion.

Methods

Materials. Western blotting analyses were performed using the following antibodies: anti PI3K-C2α, anti PI3K-C2β (BD Transduction Laboratories); anti p110α, anti p110β, anti pERK1-2 (Thr202-Tyr204), anti

---

2, *p < 0.01 vs PC3; shPI3K-C2β clone 4; *p < 0.05 vs shscrambled clone 4; **p < 0.01 vs PC3 and shscrambled clone 2. (f) Data from FBS-induced invasion assays in transiently transfected PC3 cells are expressed as average number of invaded cells/field and are means ± s.e.m. of n = 3 independent experiments performed in duplicate. *p < 0.05. (g) Data from cell counting performed in parallel with invasion assays are means ± s.e.m. of n = 4 independent experiments in duplicate. (h) Efficient downregulation of Slug was assessed by Western blotting. (i) Serum starved PC3 cells were lysed (s.free) or incubated in FBS for 24 h in the presence or absence of U0126 (25 μM) before lysis. (j) Serum starved PC3 were incubated with 50 μg/ml cycloheximide (CHX) or vehicle (DMSO) for the indicated times before lysis. (k,l) Serum starved PC3 cells were incubated with 50 μg/ml CHX or DMSO for 2 h and either lysed or incubated in FBS in the presence or absence of U0126 (25 μM) for further 24 h before lysis. Data from densitometry analysis are expressed as fold change of normalised levels of Slug in cells treated with DMSO for 2 h and are means ± s.e.m. from n = 3 independent experiments. In (j,k) tubulin was used as loading control.

---

Materials. Western blotting analyses were performed using the following antibodies: anti PI3K-C2α, anti PI3K-C2β (BD Transduction Laboratories); anti p110α, anti p110β, anti pERK1-2 (Thr202-Tyr204), anti
Cell lines and transfections. PC3 and LNCaP cell lines were maintained in RPMI-1640 or Dulbecco's modified Eagle's medium (DMEM), DU145 cells in DMEM and PNT2 cells in RPMI-1640 without phenol red. Growth medium was supplemented with 10% (v/v) FBS, 1% (v/v) of 1X penicillin/streptomycin and glutamine and 1% (v/v) sodium pyruvate. All reagents were from Life Technologies. Cells were seeded in cell culture plates and left to grow in a humidified incubator at 37 °C, 5% CO2 atmosphere. Transient transfections of siRNAs were performed using OligofectAMINE (Life Technologies) according to the manufacturer's instructions. To generate stable PC3 clones, cells were transfected with pSuper-based recombinant vectors containing either a shRNA specifically targeting PI3K-C2β (based on siRNA sequence 1) or a non-targeting siRNA (designated as ‘shRNA scrambled’) using LipofectAMINE (Life Technologies). Cell populations expressing the PI3K-C2β-targeting shRNA or shRNA scrambled were selected by incubation in growth media supplemented with 1.5 μg/ml puromycin and then allowed to grow as single clones. Individual clones were then selected, amplified and subsequently cultured in the absence of puromycin.

Western blotting analysis. Cells were left in growth media or incubated overnight in serum free DMEM, supplemented with penicillin/streptomycin and L-glutamine before stimulation with FBS or 20 ng/ml EGF. Cells were then washed and lysed either in 2% SDS or in ice-cold lysis buffer [50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 2 mM EGTA, 1 μl/ml Protease inhibitor cocktail (Sigma Aldrich), 1 μl/ml Phosphatase inhibitor cocktail A (Sigma Aldrich) and 1 μl/ml Phosphatase inhibitor cocktail B (Sigma Aldrich)]. For CHX (Sigma Aldrich) experiments, serum starved cells were incubated with serum free DMEM containing 50 μg/ml CHX or vehicle (DMSO) for the indicated times. Cells were either lysed at different times or incubated with DMEM containing 10% FBS for further 24 h. Where indicated, MEK inhibitor U0126 (25 μM) was added to the media during the 24 h incubation period. Samples were separated by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were then incubated in PBS supplemented with 0.05% (v/v) Tween 20 (PBS-T) and containing 5% skimmed milk powder for 30 min-1 h at room temperature, followed by overnight incubation with primary antibodies at +4 °C. After washing with PBS-T membranes were incubated with secondary antibodies for 1 h at room temperature, washed with PBS-T and exposed to ECL reagent. Where indicated membranes were stripped by incubation at +50 °C in SDS-based stripping buffer (62.5 mM Tris HCl pH 6.8, 0.5% SDS, 0.7% β-mercaptoethanol) for 30 min. Densitometry was performed using Image J software.

Human phosphokinase array. Analysis of the phosphorylation status of several kinases and proteins was performed using Proteome Profiler Human Phospho-Kinase Array Kit (R&D Systems) according to the manufacturer's instructions. Briefly, serum starved PC3 cells were either left untreated or incubated with FBS for 10 min. Cells were then washed in PBS and incubated with Lysis Buffer 6 for 30 min at +4 °C. Cell debris were removed by centrifugation at 14,000 × g for 5 min and protein concentration was assessed by BCA Protein Assay. After blocking in Array Buffer 1 for 1 h at room temperature each membrane was incubated with 600 μg of cell lysate overnight at +4 °C. Membranes were then washed with 1X Wash Buffer and incubated with diluted Detection Antibody Cocktail A and B for 2 h at room temperature followed by incubation with Streptavidin-HRP for additional 30 min. Membranes were then incubated with Chemi Reagent Mix and exposed on an X-ray film for 1–10 min. Densitometry analysis was performed using Image J software.

Cell Migration Assays. Random motility assay. Cells were plated in 6 well plates and transfected to an inverted contrast microscope (Zeiss Welwyn Garden City, UK) with a chamber of 37 °C, 5% CO2. Pictures were taken every 10 min for 15 h using a 10X phase contrast objective. Images were converted to movies and the motility of the cells was determined by the program MetaMorph®. All experiments were performed in duplicate.

Wound Healing Assay. Confluent cells were serum starved overnight. The following day, cells were wounded with a linear scratch using a sterile pipette tip in the presence of growth media supplemented with 10% FBS and 0.5 μg/ml mitomycin C. Timelapse microscopy was performed for 12 h. Quantitative analysis was performed by positioning a red line at time 0 and time 12 and the number of cells that had migrated into the wound area was counted.

Transwell Assay. Cells were seeded in a 6 well plate and serum starved overnight. To determine the effect of transient downregulation of PI3K-C2β, cells were transfected with the specific siRNA and serum starved overnight the day following the transfection. Where indicated polycarbonate Transwell inserts (8.0 μm diameter pores, 6.5μm diameter, Costar®) were coated overnight with 100 μg/ml Type I collagen (Sigma Aldrich) in PBS at +4 °C. Coated or uncoated inserts were then incubated in 500 μl RPMI supplemented with 0.5% BSA for 1 hour at 37 °C/5% CO2 atmosphere. Cells were resuspended in RPMI supplemented with 0.5% BSA and plated on inserts (4,000 cells for collagen-induced migration; 12,000 or 20,000 cells for FBS-induced migration). The lower chamber was filled with 500 μl of media supplemented with 10% FBS (uncoated inserts) or serum free media (coated inserts) and cells were left to migrate for 24 h (FBS) or 4 h (collagen) at 37 °C/5% CO2 atmosphere. Non-migrated cells were removed from the upper chamber using a cotton bud while cells that had migrated were fixed using 4%
paraformaldehyde for 30 min and stained with 0.1% crystal violet solution for 15 minutes. Pictures were taken from different fields using a light microscope at 10× magnification and cells were counted using the Image J program. A minimum of 10 fields were counted. All experiments were performed in duplicate.

**Cell Invasion Assay.** Cells were seeded in a 6 well plate and serum starved overnight. To determine the effect of transient downregulation of PI3K-C2β or Slug, cells were transfected with the specific siRNA and serum starved overnight the day following the transfection. The following day, Matrigel pre-coated inserts (8.0 μm diameter pores, 6.5 mm diameter, BD) were rehydrated by adding 500 μl of serum free RPMI or DMEM both in the lower and in the upper chamber for at least 1 hour at 37°C/5% CO2 atmosphere. Cells were resuspended in 500 μl serum free media and homogeneously seeded in the upper chamber (30,000 cells/insert). The lower chamber was filled with 500 μl of media containing 10% FBS or serum free media supplemented with 20 ng/ml EGF. To determine basal invasion on Matrigel serum free media was added to the lower chamber. Cells were left to invade through the Matrigel for 48 h at 37°C/5% CO2 atmosphere before being fixed, stained and counted as described above.

**Cell Growth and Cell Cycle Assays.** Cells were seeded in 12 well plates and left in growth media. Cells were manually counted at the indicated times using a Burker chamber and a light microscope at 10x magnification. All experiments were performed in duplicate.

MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cells were seeded in 12 well plates. At the indicated times, cells were incubated with 0.5 mg/ml of Thiazolyl Blue Tetrazolium Bromide (Sigma Aldrich) for 2 h at 37°C, 5% CO2 atmosphere. After washing once with PBS, 350 μl of DMSO was added to the cells for 15 min on a shaking rotor. The absorbance was read at 570–650 nm using a spectrophotometer (HT Synergy). All experiments were performed in duplicate.

Cell Cycle Analysis – Vindellövs Propidium Iodide staining. Cells were seeded in a 6 well plate (150,000 cells/well) and transfected with the indicated siRNAs. After 72 h, cells were washed once with PBS, detached and collected in 1.5 ml microfuge tubes and centrifuged at 1,200 rpm for 5 min. Pelleted cells were fixed in ice-cold 70% ethanol, washed three times in PBS, centrifuged for 5 min and resuspended in 500 μl Vindellövs Propidium Iodide solution (50 μg/ml). Cells were then analysed by flow cytometry collecting 20,000 events per sample using Fluorescence activated cell sorting (FACS) Diva software.

Apoptosis assay. Cells were plated in 6 well plates (150,000 cells/well) and transfected with the indicated siRNAs. At 48 h post transfection, cells were washed once with PBS and pelleted including the supernatant of the adherent cells. The pellet was resuspended in 400 μl 1X Annexin V Binding Buffer and 2 μl of Annexin V-FITC and incubated in the dark for 15 min at room temperature. Then, 4 μl of 4',6-diamidino-2-phenylindole (DAPI) was added and the samples were analysed by flow cytometry collecting 20,000 events per sample using FACS Diva software. A control of unstained cells was incubated only with 1X Annexin V Binding Buffer and Annexin V-FITC or DAPI in order to set the quadrants.

qPCR analysis. RNA was extracted from cells using GeneJET RNA Purification Kit (Thermo Scientific) according to the manufacturer’s instructions. The complementary DNA (cDNA) synthesis was performed on ice using Maxima Reverse Transcriptase (Thermo Scientific) according to the manufacturer’s instructions. RT-qPCR was performed using 2X Maxima SYBR green/Fluorescein (Fermentas) qPCR mix and the ABI 7500 RT-QPCR.

GAPDH cDNA was also amplified as an internal control. Primers for EMT markers were kindly provided by Prof Nullin Divecha (University of Southampton, UK). All experiments were performed in triplicate. The relative changes in gene expression quantification were calculated using the relative ddCT analysis mode of the ABI 7500 Real-Time PCR system software.

Statistical analysis. Data are expressed as means ± s.e.m. Differences between groups were analysed by Student’s t test in Excel (paired, one-tailed distribution) and p < 0.05 was considered statistically significant.

References
1. Maffucci, T. An introduction to phosphoinositides. *Curr. Top. Microbiol. Immunol.* **362**, 1–42 (2012).
2. Falasca, M. & Maffucci, T. Regulation and cellular functions of class II phosphoinositide 3-kinases. *Biochem. J.* **443**, 587–601 (2012).
3. Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. *Nat. Rev. Genet.* **7**, 606–619 (2006).
4. Wong, K. K., Engelman, J. A. & Cantley, L. C. Targeting the PI3K signaling pathway in cancer. *Curr. Opin. Genet. Dev.* **20**, 87–90 (2010).
5. Vanhaesebroeck, B., Vogt, P. K. & Rommel, C. PI3K: from the bench to the clinic and back. *Curr. Top. Microbiol. Immunol.* **347**, 1–19 (2010).
6. Zhao, L. & Vogt, P. K. Class I PI3K in oncogenic cellular transformation. *Oncogene* **27**, 5486–5496 (2008).
7. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nat. Rev. Cancer* **2**, 489–501 (2002).
8. Stephens, L., Williams, R. & Hawkins, P. Phosphoinositide 3-kinases as drug targets in cancer. *Curr. Opin. Pharmacol.* **5**, 357–365 (2005).
9. Falasca, M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. *Curr. Pharm. Des.* **16**, 1410–1416 (2010).
10. Yap, T. A., Bjerve, L., Clarke, P. A. & Workman, P. Drugging PI3K in cancer: refining targets and therapeutic strategies. *Curr. Opin. Pharmacol.* **23**, 98–107 (2015).
11. Stark, A. K., Sriskanthanarajah, S., Hessel, E. M. & Okkenhaug, K. PI3K inhibitors in inflammation, autoimmunity and cancer. *Curr. Opin. Pharmacol.* **23**, 82–91 (2015).
12. Klemmner, S. J., Myers, A. P. & Cantley, L. C. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide-3-kinase pathway. Cancer Discov. 3, 1345–1354 (2013).
13. Brown, K. K. & Toker, A. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000Prime Rep. 7, 13 (2015).
14. Vanhaesebroeck, B., Guillermot-Guibert, J., Graupera, M. & Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329–341 (2010).
15. Thorpe, L. M., Yuzgacullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7–24 (2015).
16. Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B. & Foukas, L. C. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30, 194–204 (2005).
17. Maffucci, T. & Falasca, M. New insight into the intracellular roles of class II phosphoinositide 3-kinases. Biochem. Soc. Trans. 42, 1378–1382 (2014).
18. Falasca, M. & Maffucci, T. Role of class II phosphoinositide 3-kinase in cell signalling. Biochem. Soc. Trans. 35, 211–214 (2007).
19. Yoshio, K. et al. Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat. Med. 18, 1560–1569 (2012).
20. Franco, I. et al. PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. Dev. Cell 28, 647–658 (2014).
21. Mounford, J. K. et al. The class II PI 3-kinase, PI3KC2α, links platelet internal membrane structure to shear-dependent adhesive function. Nat. Commun. 6, 6535 (2015).
22. Valet, C. et al. Essential role of class II PI3K-C2α in platelet membrane morphology. Blood 126, 1128–1137 (2015).
23. Harada, K., Truong, A. B., Cai, T. & Khavari, P. A. The class II phosphoinositide 3-kinase C2beta is not essential for epidermal differentiation. Mol. Cell. Biol. 25, 11122–11130 (2005).
24. Bracini, L. et al. PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat. Commun. 6, 7400 (2015).
25. Boller, D. et al. Targeting PI3K/C2γ impairs proliferation and survival in acute leukemia, brain tumours and neuroendocrine tumours. Anticancer Res. 32, 3015–3027 (2012).
26. Russo, A. & O’Bryan, J. P. Intersectin 1 is required for neuroblastoma tumorigenesis. Oncogene 31, 4828–4834 (2012).
27. Qian, Z., Fernald, A. A., Godley, L. A., Larson, B. A. & Le Beau, M. M. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukaemia. Proc. Natl. Acad. Sci. USA 99, 14925–14930 (2002).
28. Chiaretti, S. et al. Gene expression profiles of B-lineage adult acute lymphocytic leukaemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin. Cancer Res. 11, 7209–7219 (2005).
29. Knobbe, C. B. & Reifenberger, G. Genetic alterations and aberrant expression of genes related to the phosphatidylinositol-3-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol. 13, 507–518 (2003).
30. Liu, P. et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 33, 1270–1276 (2012).
31. Maffucci, T. et al. Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J. Cell Biol. 169, 789–799 (2005).
32. Katso, R. M. et al. Phosphoinositide-3-Kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol. Biol. Cell 17, 3729–3744 (2006).
33. Kitatani, K. et al. Ceramide limits phosphatidylinositol-3-kinase C23-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid. Oncogene 31 Sup 14, doi: 10.1038/onc.2013.330. [Epub ahead of print].
34. Russo, A., Oktar, M. N., Bosland, M. & O’Bryan, J. P. Phosphatidylinositol-3-kinase class 2 beta (PI3K(C2)β) isoform contributes to neuroblastoma tumorigenesis. Cancer Lett. 359, 262–268 (2015).
35. Arcaro, A. et al. Two distinct phosphoinositide-3-kinases mediate polyolipid growth factor-stimulated PKB activation. EMBO J. 21, 5097–5108 (2002).
36. Blajecka, K. et al. Phosphoinositide-3-kinase C2γ regulates RhoA and the actin cytoskeleton through an interaction with DbI. PLoS One 7, e44945 (2012).
37. Domen, J. et al. The class II phosphoinositide 3-kinase PI3K-C2β regulates cell migration by a PtdIns3P-dependent mechanism. J. Cell. Physiol. 205, 452–462 (2005).
38. Koutros, S. et al. Pooled analysis of phosphatidylinositol-3-kinase pathway variants and risk of prostate cancer. Cancer Res. 70, 2389–2396 (2010).
39. Arcaro, A. et al. Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J. Biol. Chem. 297, 33082–33090 (2002).
40. Tribolla, G. et al. Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. PLoS One 8, e35808 (2013).
41. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer. 2, 442–454 (2002).
42. Emadi Bagyi, M. et al. Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biol. 31, 297–307 (2010).
43. Uygur, B. & Wu, W. S. SLUG promotes prostate cancer cell migration and invasion via CXCRA4/CXCL12 axis. Mol. Cancer 10, 139 (2011).
44. Ding, G. et al. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signalling to increase SLUG expression in prostate cancer. Prostate 75, 957–968 (2015).
45. Amatangelo, M. D., Goodyear, S., Varma, D. & Stearns, M. E. c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer. Carcinogenesis 33, 1965–1975 (2012).
46. Gan, Y. et al. Differential roles of ERK and Akt pathways in regulation of EGF-mediated signalling and motility in prostate cancer cells. Oncogene 29, 4947–4958 (2010).
47. Xiao, L. J. et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int. J. Oncol. 40, 1714–1724 (2012).
48. Barrallo-Gimeno, A. & Nieto, M. A. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 132, 3151–3161 (2005).
49. Tania, M., Khan, M. A. & Fu, J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 35, 7335–7342 (2014).
50. Wang, Y., Shi, J., Chai, K., Ying, X. & Zhou, B. P. The Role of Snail in EMT and Tumorigenesis. Curr. Cancer Drug Targets 13, 963–72 (2013).
51. Ding, G. et al. Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition. PLoS One 8, e77400 (2013).
52. Taylor, B. S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11–22 (2010).
53. Hollander, M. C., Blumenthal, G. M. & Dennis, P. A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11, 289–301 (2011).
54. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348–355 (1998).
55. Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209–221 (2003).
56. Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E9 (2003).
57. Jia, S. et al. Essential roles of PI (3) K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454, 776–779 (2008).
58. Lee, S. H. et al. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc. Natl. Acad. Sci. USA 107, 11002–11007 (2010).
59. Li, B., Sun, A., Jiang, W., Thrasher, J. R. & Terranova, P. PI-3 kinase p110β: a therapeutic target in advanced prostate cancers. Am. J. Clin. Exp. Urol. 2, 188–198 (2014).
60. Chen, R. et al. Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice. Prostate 75, 593–602 (2015).

Acknowledgements
This work was supported by Prostate Cancer UK (grant PG13-029 to T.M. and to M.F.). O.C. is supported by Prostate Cancer UK (grant PG13-029 to T.M. and to M.F.). Work in M.F.’s lab is supported by Prostate Cancer UK (grant PG12-23). I.M. was supported by a MRC Doctoral Training Award to Barts and The London School of Medicine and Dentistry. We would like to thank Prof. Nullin Divecha (University of Southampton, UK) for providing primers for qPCR analysis.

Author Contributions
I.M., O.C. and T.M. designed and performed the experiments; T.M. and M.F. conceived the experiments; I.M. wrote the Methods section; M.F. contributed to manuscript writing; T.M. led and supervised the whole study and wrote the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Mavrommati, I. et al. Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion. Sci. Rep. 6, 23277; doi: 10.1038/srep23277 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/